Clinical Research Directory
Browse clinical research sites, groups, and studies.
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer
Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Summary
Conducting an early phase clinical trial to assess CEA Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of CEA positive rectal cancer patients. 1. Treat CEA positive rectal cancer via Trained Immunity. 2. Activate human CEA Protein Antigen Presentation Reaction. 3. The human antigen presenting cells (APCs) can treat the CEA protein antigen into small peptide fragments, and then kill CEA positive rectal cancer cells in vivo.
Official title: Conducting an Early Phase Clinical Trial to Assess for CEA Antigen Presentation Therapeutic Biological Product Mix Activity That Suggests the Potential for Clinical Benefits of CEA Positive Rectal Cancer Patients.
Key Details
Gender
All
Age Range
24 Years - 64 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2021-12-28
Completion Date
2026-02-28
Last Updated
2025-06-17
Healthy Volunteers
No
Conditions
Interventions
CEA protein antigen plus BCG Vaccine Mix for percutaneous use
* By the percutaneous route with the multiple puncture device * CEA protein antigen 0.05 mg plus BCG Organism 50 MG Mix
Locations (1)
Medicine Invention Design, Inc. (MIDI) - c/o - IORG0007849 - NPI-1023387701
Rockville, Maryland, United States